← Back to Search

Monoclonal Antibodies

Tocilizumab for Interstitial Lung Disease

Phase 2
Waitlist Available
Research Sponsored by Peking Union Medical College Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
RP-ILD, previous or concurrent diagnosis of systemic diseases
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Summary

There is no confirmed drug therapy for RP-ILD. Prognosis is poor of regular treatment. The study is designed to compare efficacy and safety of tocilizumab versus regular treatment in participants with severe RP-ILD secondary to systemic diseases.

Eligible Conditions
  • Interstitial Lung Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The differences of oxygenation index changes between the two groups on day 7, 14, 28 and month 3 after the first dose*
Secondary outcome measures
Changes of dyspnea index
Changes of erythrocyte sedimentation rate, c-reactive protein or ferritin at baseline and on day 3, 7, 14, 28, month 3 after the first dose
Computed tomography score
+7 more

Side effects data

From 2017 Phase 4 trial • 59 Patients • NCT02034474
11%
Low ANC
5%
nausea
5%
Inpatient admission
5%
fatigue
5%
agranulocytosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tocilizumab
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TocilizumabExperimental Treatment1 Intervention
Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab. No Intervention: control, participants in control group will receive regular treatment.
Group II: ControlActive Control1 Intervention
Participants in control group will receive regular treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tocilizumab
FDA approved

Find a Location

Who is running the clinical trial?

Peking Union Medical College HospitalLead Sponsor
1,061 Previous Clinical Trials
2,278,913 Total Patients Enrolled
Xinlun Tian, M.D.Study DirectorPeking Union Medical College Hospital
~16 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top